对CNC-BZIP成员NFE2L3的新见解
New insight into the CNC-bZIP member, NFE2L3, in human diseases
影响因子:4.30000
分区:生物学2区 / 发育生物学2区 细胞生物学3区
发表日期:2024
作者:
Guanghui Xiong, Jie Li, Fuli Yao, Fang Yang, Yuancai Xiang
摘要
Nuclear factor erythroid 2 (NF-E2)-related factor 3 (NFE2L3), a member of the CNC-bZIP subfamily and widely found in a variety of tissues, is an endoplasmic reticulum (ER) membrane-anchored transcription factor that can be released from the ER and moved into the nucleus to bind the promoter region to regulate a series of target genes involved in antioxidant, inflammatory反应和细胞周期对细胞外或细胞内应激的调节。最近的研究，特别是在过去的5年中，已经阐明了NFE2L3参与各种生物学过程，包括细胞分化，炎症反应，脂质稳态，免疫反应和肿瘤生长。值得注意的是，NFE2L3已被确定为多种癌症发展和预后的关键参与者，包括大肠癌，甲状腺癌，乳腺癌，肝癌，肝细胞癌，胃癌，肾脏癌，膀胱癌，食管性鳞状细胞癌，T细胞细胞淋巴瘤淋巴瘤淋巴瘤，癌症，肉体癌，肉体癌。此外，研究已将NFE2L3与其他癌症联系起来，例如肺腺癌，恶性胸膜间皮瘤，卵巢癌，多形胶质细胞瘤和喉癌，表明其潜在的创新癌症治疗方法的靶标。因此，为了更好地了解NFE2L3在疾病中的作用，本综述为NFE2L3研究的发现，结构，功能和最新进步提供了见解，以为开发NFE2L3靶向的癌症疗法开发奠定基础。
Abstract
Nuclear factor erythroid 2 (NF-E2)-related factor 3 (NFE2L3), a member of the CNC-bZIP subfamily and widely found in a variety of tissues, is an endoplasmic reticulum (ER) membrane-anchored transcription factor that can be released from the ER and moved into the nucleus to bind the promoter region to regulate a series of target genes involved in antioxidant, inflammatory responses, and cell cycle regulation in response to extracellular or intracellular stress. Recent research, particularly in the past 5 years, has shed light on NFE2L3's participation in diverse biological processes, including cell differentiation, inflammatory responses, lipid homeostasis, immune responses, and tumor growth. Notably, NFE2L3 has been identified as a key player in the development and prognosis of multiple cancers including colorectal cancer, thyroid cancer, breast cancer, hepatocellular carcinoma, gastric cancer, renal cancer, bladder cancer, esophageal squamous cell carcinoma, T cell lymphoblastic lymphoma, pancreatic cancer, and squamous cell carcinoma. Furthermore, research has linked NFE2L3 to other cancers such as lung adenocarcinoma, malignant pleural mesothelioma, ovarian cancer, glioblastoma multiforme, and laryngeal carcinoma, indicating its potential as a target for innovative cancer treatment approaches. Therefore, to gain a better understanding of the role of NFE2L3 in disease, this review offers insights into the discovery, structure, function, and recent advancements in the study of NFE2L3 to lay the groundwork for the development of NFE2L3-targeted cancer therapies.